OBI 3424

Drug Profile

OBI 3424

Alternative Names: OBI-3424; TH-3424

Latest Information Update: 20 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Threshold Pharmaceuticals
  • Developer Ascenta Pharmaceuticals; National Cancer Institute (USA); OBI Pharma; Threshold Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liver cancer; Prostate cancer
  • Preclinical Precursor T-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 19 Sep 2018 OBI 3424 receives Orphan Drug status for Precursor cell lymphoblastic leukaemia-lymphoma in USA
  • 09 Jul 2018 Phase-I/II clinical trials in liver cancer in USA
  • 09 Jul 2018 Phase-I/II clinical trials in Prostate cancer (Hormone refractory) in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top